Biotech News

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Esperion Therapeutics (ESPR)Esperion Therapeutics2026-06-25 13:46 ESTCompany update

ANN ARBOR, Mich., May 14, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on May 12 2026, the Company granted 23 new employees 260,000 restricted stock units (RSUs) under Esperion’s 2017 Inducement Equity Incentive Plan. The 2017 Inducement Equity Incentive Plan is used

Open original release

Related news

ESPREsperion Therapeutics2026-06-25 13:46 EST

Esperion Presents New Data from CLEAR Outcomes and the CLEAR PATH Phase 2 Pediatric Study at the European Atherosclerosis Society Congress 2026

ESPREsperion Therapeutics2026-06-25 13:46 EST

Esperion Announces Two New Analyses Supporting Bempedoic Acid to Reduce LDL-C Levels to be Presented at the European Atherosclerosis Society (EAS) Congress 2026

ESPREsperion Therapeutics2026-06-25 13:46 EST

Esperion to Report Fourth Quarter and Full Year 2025 Financial Results on March 10

ESPREsperion Therapeutics2026-06-25 13:46 EST

Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

ESPREsperion Therapeutics2026-06-25 13:46 EST

Esperion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

ESPREsperion Therapeutics2026-06-25 13:46 EST

Esperion’s Bempedoic Acid Receives Multiple Class 1 Recommendations in 2026 ACC/AHA Multisociety Guideline for Management of Dyslipidemia

ESPREsperion Therapeutics2026-06-25 13:46 EST

Esperion to Present Two New Analyses from CLEAR Outcomes Clinical Trial at the American College of Cardiology 2026 Annual Scientific Session

ESPREsperion Therapeutics2026-06-25 13:46 EST

Esperion Showcases New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) at the American College of Cardiology’s Annual Scientific Session 2026

ESPREsperion Therapeutics2026-06-25 13:46 EST

Esperion to Participate in 25th Annual Needham Virtual Healthcare Conference

ESPREsperion Therapeutics2026-06-25 13:46 EST

Esperion Therapeutics Closes Acquisition of Corstasis Therapeutics, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

View all latest news

Esperion Therapeutics

Esperion Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

ESPREsperion Therapeutics2026-06-26 12:00 EST

Esperion Presents New Data from CLEAR Outcomes and the CLEAR PATH Phase 2 Pediatric Study at the European Atherosclerosis Society Congress 2026

ESPREsperion Therapeutics2026-06-26 12:00 EST

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

ESPREsperion Therapeutics2026-06-26 12:00 EST

Esperion Announces Two New Analyses Supporting Bempedoic Acid to Reduce LDL-C Levels to be Presented at the European Atherosclerosis Society (EAS) Congress 2026

ESPREsperion Therapeutics2026-06-26 12:00 EST

Esperion to Report Fourth Quarter and Full Year 2025 Financial Results on March 10

ESPREsperion Therapeutics2026-06-26 12:00 EST

Esperion Therapeutics and Corstasis Therapeutics Announce Esperion’s Definitive Agreement to Acquire Corstasis, Expanding Its Cardiovascular Franchise with Enbumyst™ (bumetanide nasal spray)

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States